Camlin Fine Sciences Ltd
₹ 107
0.11%
26 Aug
- close price
About
Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.
Key Points
- Market Cap ₹ 2,047 Cr.
- Current Price ₹ 107
- High / Low ₹ 235 / 96.2
- Stock P/E
- Book Value ₹ 54.2
- Dividend Yield 0.00 %
- ROCE 4.78 %
- ROE 3.75 %
- Face Value ₹ 1.00
Pros
- Company's working capital requirements have reduced from 35.3 days to 22.6 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.74% over past five years.
- Company has a low return on equity of -6.99% over last 3 years.
- Earnings include an other income of Rs.63.6 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities BSE 1000
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,629 | 1,723 | 1,845 | |
| 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,471 | 1,284 | 1,402 | 1,605 | 1,761 | |
| Operating Profit | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 211 | 170 | 227 | 118 | 84 |
| OPM % | 15% | 19% | 6% | 2.2% | 8% | 13% | 16% | 11% | 13% | 12% | 14% | 7% | 4.6% |
| 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -218 | 59 | 64 | |
| Interest | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 64 | 70 | 107 | 83 | 73 |
| Depreciation | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 61 | 71 | 75 |
| Profit before tax | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -159 | 23 | -0 |
| Tax % | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | -0% | -2% | |
| 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | 24 | 1 | |
| EPS in Rs | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | 1.44 | 0.29 |
| Dividend Payout % | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 8% |
| 3 Years: | 1% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -6% |
| 3 Years: | -14% |
| TTM: | -139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -9% |
| 3 Years: | -11% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -7% |
| Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 1,022 |
| 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 652 | 720 | |
| 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 467 | 559 | |
| Total Liabilities | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
| 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 887 | |
| CWIP | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 33 |
| Investments | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 30 |
| 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,246 | 1,370 | |
| Total Assets | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46 | 72 | -9 | -15 | -9 | 86 | 117 | 145 | 51 | 139 | 23 | 82 | |
| -26 | -66 | -70 | -149 | -2 | -90 | -133 | -249 | -125 | -66 | -75 | -53 | |
| -15 | -7 | 91 | 182 | 26 | 3 | 39 | 136 | 60 | -86 | 76 | -25 | |
| Net Cash Flow | 4 | -1 | 13 | 18 | 15 | -1 | 23 | 32 | -14 | -13 | 24 | 4 |
| Free Cash Flow | 19 | 5 | -39 | -34 | -78 | -48 | 34 | -68 | -93 | 79 | -19 | 20 |
| CFO/OP | 68% | 91% | 5% | -33% | 10% | 77% | 82% | 111% | 34% | 110% | 27% | 90% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 74 | 79 |
| Inventory Days | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 234 | 199 |
| Days Payable | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 180 | 200 |
| Cash Conversion Cycle | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 127 | 78 |
| Working Capital Days | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 33 | 23 |
| ROCE % | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 12% | 5% |
Insights
In beta| Jun 2020 | Feb 2022 | Feb 2023 | Aug 2024 | May 2026 | |
|---|---|---|---|---|---|
| Blends Formulations Count count |
|
||||
| Number of Countries Presence count |
|||||
| Number of Global Manufacturing Facilities count |
|||||
| Range of Products count |
|||||
| Customer Base count |
|||||
| Dahej Diphenol (HQ+Catechol) Plant Capacity Utilization % |
|||||
| Vanillin Sales Volume MT |
|||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication - Unaudited Financial Results for the quarter ended June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of Q1 FY27 results conference call posted on company website.
- Announcement under Regulation 30 (LODR)-Investor Presentation
-
Board Meeting Outcome for Outcome Of Board Meeting Dated August 11, 2026
- Board approved Q1 FY27 unaudited results; consolidated revenue Rs 5,198.79 million, loss Rs 336.22 million.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Dec 2019TranscriptAI SummaryPPT
-
Dec 2019TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
May 2016TranscriptAI SummaryPPT
Business Verticals
[1] [2]
a) Specialty Ingredients (76% in FY26 vs 77% in FY25): [3] [4]
The company is a global leader in antioxidant manufacturing, offering customised antioxidant and shelf-life solutions for applications across food, pet nutrition, biodiesel, and livestock industries under key brands like NaSure, Xtendra, Biosus Omega, Biosus DHA, etc. Products under this segment are divided into: